Clinical Trials on No-Reflow Phenomenon in Chile

Total 8 results

Pontificia Universidad Catolica de Chile

Completed

Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud

Lupus Erythematosus, Systemic | Dermatomyositis | Ultrasound Therapy; Complications | Raynaud Disease | Raynaud Phenomenon Due to Trauma | System; Sclerosis

Chile
Cirujanos la Serena

Completed

Pancreaticobiliary Reflux in Patients Without Cholelithiasis

Pancreaticobiliary Reflux

Chile
EndoStim Inc.

Completed

Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease

Gastroesophageal Reflux Disease

Chile
AstraZeneca

Completed

A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) (NEON)

Gastroesophageal Reflux Disease

Chile, Argentina, Venezuela, Colombia
EndoStim Inc.

Unknown

Effect of Long-Term Electrical Stimulation on LES Pressure and Esophageal Acid Exposure in Patients With GERD

Gastroesophageal Reflux Disease

Chile, Colombia, India, Mexico, Netherlands, New Zealand, United Kingdom
Pontificia Universidad Catolica de Chile

Unknown

Common Neonatal Procedures Could Affect the aEEG in <30 Weeks of Gestational Age Preterms (ELECTROPREM)

Premature Birth | Electroencephalography | Regional Blood Flow

Chile
Eisai Inc.

Completed

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

Chile, Canada, United States, Estonia, India, Hungary, Bulgaria, Croatia, Australia, Lithuania, Latvia, Argentina, France, Germany
Eisai Inc.

Completed

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

Canada, Chile, Hungary, Bulgaria, Estonia, Latvia, United States, Croatia, Australia, India, Argentina, France, Germany

Clinical Trials on No-Reflow Phenomenon in Chile

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations